Silexion Therapeutics implements 1-for-24 reverse share split
SLXN•Silexion Therapeutics implemented a 1-for-24 reverse share split covering outstanding and authorized but unissued ordinary shares. Warrant adjustments took effect after the November 10, 2026, close, with the exercise price rising 24-fold to $372,600 per whole post-split ordinary share.
1. Split and warrant terms
Silexion Therapeutics implemented a 1-for-24 reverse share split covering outstanding ordinary shares and authorized but unissued ordinary shares. Public and private warrant adjustments took effect following the November 10, 2026, trading close and were reflected at the November 11 open. Each pre-split warrant now entitles its holder to 1/24th of an ordinary share, and the exercise price rose 24-fold to $372,600 per whole post-split ordinary share.
